WASHINGTON (AP) Researchers for the first time will conduct studies directly linking cancer patients with the new science of proteomics, a study of all the proteins in living cells.
Federal officials announced Friday that the Food and Drug Administration and the National Cancer Institute are establishing a joint research lab designed to develop cancer therapies and diagnosis systems based on the study of proteins.
The effort, called the Clinical Proteomics Program, holds the potential to revolutionize cancer detection and care, said Tommy G. Thompson, the secretary of Health and Human Services, the parent department of both FDA and NCI.
With this expanded collaboration, the FDA and NCI are employing powerful new technologies they developed jointly, said Thompson in a statement.
The new program will be funded at $1.1 million a year for three years, the agencies announced.
Experts say proteomics offers the hope of identifying, on a molecular scale, the proteins produced in a cell that may relate to cancer, its diagnosis and its treatment.
Copyright © 2001, Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.